Open access
Aug 2026
EGFR inhibition promotes functional engraftment and graft survival via donor-derived CHI3L1 in fetal RPE suspension transplantation
It is demonstrated that repurposing Food and Drug Administration (FDA)-approved EGFR inhibitor offers a safe and cost-effective approach to advancing fetal RPE suspension transplantation into clinical practice.
Xiying Mao, Wen-Jie Yin, Miao Xu et al.
· Cell Reports Medicine · 0 citations